Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- CHM ceases enrolment in Phase 1 trial and Company update
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics